PPLPHARMA Is India Consumer Healthcare Business Comprising Analgesics, Skin Care, Vitamin/mineral Supplement, Kids’ Wellness, Digestives, Women’s Health, And Hygiene And Protection. PPLPHARMA Is At Support Level Of 214-216 Breakout A Trendline With Non Avrage Voloume Buy @235 Target 1. 250 2. 300 3. 350 " Happy Diwali "
Nice pattern with good time of cosolidation on 1hr time frame buy if high gets break dont jump directly enter on bullish candle
Ltts at breakout pattern Key points : - 1. Rsi 60 crossing on monthly chart 2. Dii increase thier holding in company 3. Weekly rsi above 60 THIS NOT BUY SELL SIGNAL JUST ADD TO YOUR WATCHLIST AFTER BREAKOUT YOU CAN CONSIDER
Stock is ready for breakout at level of 950 to buy fii and dii increse thir holding continusoly stocks deliver good financialsupport to technical stock form 2 year of cup with strong breakout now if you see on weekly candle aftera breakout candle pause nad then ready to buy
Key points : - 1. Crossed 60 on monthly chart 2. Taking support on weekly rsi 3. Outperform sector 4. Sectors storngest stock 5. Buy above 1700 is great buy 6. But after a sep fed cut buy will we be more strong ...
long consolidation with higher level sustain grat buying opportunities
stock performing very good finacials with the support of technical very small pattern like w pattern breakout level at 800 1st cup breakout at 1200 2nd cup breakout at 1700 3rd and most important breakout is going at level of 2150 Fundamentals of the stock are supporting the technicals which makes it a best buy
Best buy above 450 NSE:GICRE Nice buying opportunities rsi rsi taking 60 support on monthly candle Fii holdng increase Dii holding increase 85 % promoter holdin
IMPORTANT POINTS 1. RSI - 60 CROSSED ON MONTHLY CHART 2. CUP BREAKOUT OVER ONE YEAR 3. SECTOR BREAKOUT 4. Trading at 35.2% below our estimate of its fair value FUNDAMENTALS Below Fair Value Significantly Below Fair Value Price-To-Sales vs Peers Price-To-Sales vs Industry Price-To-Sales vs Fair Ratio
Union Minister of Health and Family Welfare Shri Nadda said: “The initiation of this Phase III clinical trial for India’s first indigenous dengue vaccine marks a critical advancement in our fight against dengue. It reflects our commitment to protecting our citizens from this pervasive disease and underscores India’s capabilities in vaccine research and...
Technicals: RSI > 65 on all time frame Huge Volume on daily time frame Rising price with proper base formation Fundamentals : Promotor/ FII / DII : increasing stake for 3 consecutive Qtrs EPS : Increasing 4 consecutive Qtrs Sequential Targets : 420 / 460 / 510 / 580 / 660